Puma Biotechnology, Inc.(PBYI)Earnings, Financials & Key Ratios

PBYI•NASDAQ

$7.45

$379M mkt cap·12.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryOncology Therapeutics Developers

AboutPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Show more

Revenue$228M-0.9%
EBITDA$48M+13.5%
Net Income$31M+2.8%
EPS (Diluted)0.61-1.6%
Gross Margin74.53%+3.4%
EBITDA Margin21.12%+14.6%
Operating Margin16.33%+21.6%
Net Margin13.62%+3.7%
ROE27.97%-32.8%
ROIC24.73%-5.6%
Debt/Equity0.22-72.8%
Interest Coverage6.40+118.1%

Technical→

PBYI Key Insights

Puma Biotechnology, Inc. (PBYI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 42.4%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 18.3% free cash flow margin
✓Momentum leader: RS Rating 85 (top 15%)
✓High quality earnings: Operating CF exceeds net income
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

PBYI Price & Volume

Puma Biotechnology, Inc. (PBYI) stock price & volume — 10-year historical chart

Loading chart...

PBYI Growth Metrics

Puma Biotechnology, Inc. (PBYI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years0.29%

3 Years0.05%

TTM-0.89%

Profit CAGR

10 Years-

5 Years-

3 Years2396.29%

TTM2.63%

EPS CAGR

10 Years-

5 Years-

3 Years210.89%

TTM0.54%

Return on Capital

10 Years-34.53%

5 Years19.47%

3 Years26.06%

Last Year29.57%

PBYI Recent Earnings

Puma Biotechnology, Inc. (PBYI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.29

Est $0.24

+20.8%

Revenue

$60M

Est $69M

-12.7%

Q4 2025

Nov 6, 2025

EPS

$0.21

Est $0.09

+133.3%

Revenue

$54M

Est $69M

-20.6%

Q3 2025

Aug 7, 2025

EPS

$0.15

Est $0.11

+36.4%

Revenue

$52M

Est $51M

+2.8%

Q2 2025

May 8, 2025

EPS

$0.10

Est $0.02

+400.0%

Revenue

$46M

Est $53M

-12.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.29vs $0.24+20.8%	$60Mvs $69M-12.7%
Q4 2025	Nov 6, 2025	$0.21vs $0.09+133.3%	$54Mvs $69M-20.6%
Q3 2025	Aug 7, 2025	$0.15vs $0.11+36.4%	$52Mvs $51M+2.8%
Q2 2025	May 8, 2025	$0.10vs $0.02+400.0%	$46Mvs $53M-12.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
RCUSArcus Biosciences, Inc.Direct Competitor	2.62B	26.00	-7.90	-4.26%	-156.36%	-68.97%	0.16
TGTXTG Therapeutics, Inc.Direct Competitor	6.7B	41.97	15.15	87.32%	65.95%	87.36%	0.40
PTCTPTC Therapeutics, Inc.Direct Competitor	5.52B	66.61	8.56	114.51%	39.44%
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.68B	21.48	9.38	11.87%	36.49%	41.9%	0.04
EXELExelixis, Inc.Product Competitor	12.37B	48.70	17.52	6.98%	35.08%	40.21%	0.08
NKTRNektar TherapeuticsProduct Competitor	1.67B	85.09	-8.75	-43.89%	-192.87%	-356.81%	0.95
PFEPfizer Inc.Supply Chain	150.77B	26.51	19.49	-1.65%	11.83%	8.34%	0.78
AZNAstraZeneca PLCSupply Chain	286.68B	184.92	28.28	8.63%	17.19%	22.24%	0.61

Compare PBYI vs Peers

Puma Biotechnology, Inc. (PBYI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RCUS

Most directly comparable listed peer for PBYI.

Scale Benchmark

vs AZN

Larger-name benchmark to compare PBYI against a more recognizable public peer.

Peer Set

Compare Top 5

vs RCUS, TGTX, PTCT, ACAD

PBYI Income Statement

Puma Biotechnology, Inc. (PBYI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	27.7M	251M	272.26M	225.11M	253.16M	228.03M	235.64M	230.47M	228.37M
Revenue Growth %	-	806.14%	8.47%	-17.32%	12.46%	-9.92%	3.34%	-2.19%	-0.91%
Cost of Goods Sold	5.6M	34.6M	36.81M	39.37M	63.7M	55.09M	62.68M	64.4M	58.16M
COGS % of Revenue	20.22%	13.78%	13.52%	17.49%	25.16%	24.16%	26.6%	27.94%	25.47%
Gross Profit	22.1M▲ 0%	216.4M▲ 879.2%	235.44M▲ 8.8%	185.74M▼ 21.1%	189.45M▲ 2.0%	172.94M▼ 8.7%	172.96M▲ 0.0%	166.06M▼ 4.0%	170.21M▲ 2.5%
Gross Margin %	79.78%	86.22%	86.48%	82.51%	74.84%	75.84%	73.4%	72.06%	74.53%
Gross Profit Growth %	2023.41%	879.19%	8.8%	-21.11%	2%	-8.72%	0.01%	-3.98%	2.5%
Operating Expenses	314.5M	311.1M	311.04M	216.14M	188.16M	149.22M	140.31M	135.1M	132.91M
OpEx % of Revenue	1135.38%	123.94%	114.24%	96.01%	74.33%	65.44%	59.55%	58.62%	58.2%
Selling, General & Admin	106.7M	146.2M	141.64M	118.49M	116.29M	89.98M	89.31M	80.16M	70.85M
SG&A % of Revenue	385.2%	58.25%	52.02%	52.64%	45.94%	39.46%	37.9%	34.78%	31.02%
Research & Development	207.8M	164.9M	132.85M	97.65M	71.87M	52.24M	50.38M	54.94M	62.07M
R&D % of Revenue	750.18%	65.7%	48.8%	43.38%	28.39%	22.91%	21.38%	23.84%	27.18%
Other Operating Expenses	-100K	0	36.55M	0	0	7M	625K	0	0
Operating Income	-292.4M▲ 0%	-94.7M▲ 67.6%	-75.59M▲ 20.2%	-30.4M▲ 59.8%	1.29M▲ 104.2%	23.72M▲ 1738.8%	32.64M▲ 37.6%	30.97M▼ 5.1%	37.3M▲ 20.5%
Operating Margin %	-1055.6%	-37.73%	-27.77%	-13.51%	0.51%	10.4%	13.85%	13.44%	16.33%
Operating Income Growth %	-5.71%	67.61%	20.17%	59.78%	104.24%	1738.76%	37.61%	-5.13%	20.45%
EBITDA	-289.59M	-87.32M	-67.52M	-20.37M	12.6M	33.56M	44.16M	42.49M	48.24M
EBITDA Margin %	-1045.45%	-34.79%	-24.8%	-9.05%	4.98%	14.72%	18.74%	18.44%	21.12%
EBITDA Growth %	-5.13%	69.85%	22.67%	69.83%	161.83%	166.45%	31.58%	-3.78%	13.53%
D&A (Non-Cash Add-back)	2.81M	7.38M	8.08M	10.03M	11.3M	9.84M	11.52M	11.52M	10.94M
EBIT	-291.24M	-102.59M	-60.52M	-45.74M	-15.99M	12.05M	36M	36.55M	42.4M
Net Interest Income	536K	-9.19M	-12.17M	-13.56M	-12.65M	-10.78M	-10.72M	-7.73M	-2.54M
Interest Income	1.26M	1.8M	2.8M	489K	160K	813K	2.6M	4.72M	4.08M
Interest Expense	720K	11M	15M	14.05M	12.81M	11.59M	13.33M	12.45M	6.62M
Other Income/Expense	435K	-18.92M	53K	-29.39M	-30.09M	-23.26M	-9.97M	-6.87M	-1.52M
Pretax Income	-292M▲ 0%	-113.6M▲ 61.1%	-75.54M▲ 33.5%	-59.79M▲ 20.9%	-28.8M▲ 51.8%	457K▲ 101.6%	22.67M▲ 4861.5%	24.1M▲ 6.3%	35.78M▲ 48.5%
Pretax Margin %	-1054.15%	-45.26%	-27.75%	-26.56%	-11.38%	0.2%	9.62%	10.46%	15.67%
Income Tax	-2.21M	-7.92M	53K	207K	324K	455K	1.08M	-6.18M	4.67M
Effective Tax Rate %	0.76%	6.97%	-0.07%	-0.35%	-1.12%	99.56%	4.78%	-25.63%	13.05%
Net Income	-292M▲ 0%	-113.6M▲ 61.1%	-75.59M▲ 33.5%	-59.99M▲ 20.6%	-29.13M▲ 51.5%	2K▲ 100.0%	21.59M▲ 1079450.0%	30.28M▲ 40.2%	31.11M▲ 2.8%
Net Margin %	-1054.15%	-45.26%	-27.77%	-26.65%	-11.51%	0%	9.16%	13.14%	13.62%
Net Income Growth %	-5.8%	61.1%	33.46%	20.64%	51.45%	100.01%	1079450%	40.23%	2.75%
Net Income (Continuing)	-291.95M	-113.58M	-75.59M	-59.99M	-29.13M	2K	21.59M	30.28M	31.11M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-7.86▲ 0%	-2.99▲ 62.0%	-2.13▲ 28.8%	-1.52▲ 28.6%	-0.72▲ 52.6%	0.02▲ 102.8%	0.45▲ 2116.7%	0.62▲ 37.8%	0.61▼ 1.6%
EPS Growth %	5.19%	61.96%	28.76%	28.64%	52.63%	102.82%	2116.75%	37.78%	-1.61%
EPS (Basic)	-7.86	-2.99	-2.13	-1.52	-0.72	0.02	0.46	0.62	0.62
Diluted Shares Outstanding	37.17M	37.94M	38.77M	39.58M	40.64M	44.93M	47.55M	49.1M	50.65M
Basic Shares Outstanding	37.17M	37.94M	38.77M	39.58M	40.64M	44.67M	47.13M	48.65M	50.01M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

PBYI Balance Sheet

Puma Biotechnology, Inc. (PBYI) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	106.39M	203M	166.3M	146.14M	140.02M	134.28M	156.19M	147.66M	162.69M
Cash & Short-Term Investments	81.7M	108.4M	111.64M	93.39M	82.11M	81.07M	95.94M	100.97M	97.53M
Cash Only	81.7M	108.4M	60.04M	85.29M	63.13M	76.2M	84.58M	69.22M	29.64M
Short-Term Investments	0	0	51.61M	8.1M	18.98M	4.87M	11.35M	31.75M	67.89M
Accounts Receivable	9.67M	21.95M	28.9M	25.54M	32.53M	42.27M	48.49M	32.01M	53.65M
Days Sales Outstanding	127.42	31.92	38.74	41.42	46.9	67.66	75.11	50.7	85.75
Inventory	2.03M	2.63M	3.17M	3.45M	7.11M	4.53M	7.08M	8.72M	5.51M
Days Inventory Outstanding	132.25	27.69	31.43	32.02	40.73	29.99	41.23	49.44	34.61
Other Current Assets	11.69M	3.85M	11.74M	11.75M	11.43M	1.95M	260K	3.7M	5.99M
Total Non-Current Assets	59.13M	56.12M	68.61M	98.08M	86.56M	87.78M	74.34M	65.67M	53.62M
Property, Plant & Equipment	4.47M	3.96M	21.83M	18.89M	15.77M	12.51M	8.65M	5.09M	5.56M
Fixed Asset Turnover	6.20x	63.34x	12.47x	11.92x	16.05x	18.23x	27.25x	45.24x	41.07x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	48.35M	44.41M	40.46M	74.14M	66.13M	70.61M	60.87M	51.13M	41.39M
Long-Term Investments	4.32M	2K	0	0	0	0	2.09M	0	0
Other Non-Current Assets	6.31M	6.01M	6.32M	5.06M	4.67M	4.66M	2.73M	2.38M	2.83M
Total Assets	165.53M▲ 0%	259.12M▲ 56.5%	234.91M▼ 9.3%	244.22M▲ 4.0%	226.59M▼ 7.2%	222.06M▼ 2.0%	230.53M▲ 3.8%	213.33M▼ 7.5%	216.3M▲ 1.4%
Asset Turnover	0.17x	0.97x	1.16x	0.92x	1.12x	1.03x	1.02x	1.08x	1.06x
Asset Growth %	-34.52%	56.55%	-9.35%	3.97%	-7.22%	-2%	3.81%	-7.46%	1.39%
Total Current Liabilities	58.34M	67.11M	90.84M	114.25M	109.59M	77.48M	99.38M	96.11M	81.25M
Accounts Payable	27.69M	20.68M	19.18M	12.08M	11.17M	6.44M	6.89M	5.51M	5.06M
Days Payables Outstanding	1.8K	218.2	190.19	111.95	64.03	42.67	40.11	31.22	31.73
Short-Term Debt	0	0	0	14.29M	0	0	34M	45.33M	23.84M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	27.85M	40.29M	5.76M	15.09M	11.22M	13.34M	43.42M	39.73M	52.36M
Current Ratio	1.82x	3.02x	1.83x	1.28x	1.28x	1.73x	1.57x	1.54x	2.00x
Quick Ratio	1.79x	2.99x	1.80x	1.25x	1.21x	1.67x	1.50x	1.45x	1.93x
Cash Conversion Cycle	-1.55K	-158.59	-120.02	-38.51	23.6	54.98	76.22	68.92	88.63
Total Non-Current Liabilities	53.88M	157.7M	126.61M	135.92M	119.44M	122.97M	77.7M	25.1M	4.71M
Long-Term Debt	48.48M	151.89M	94.96M	84.03M	97.09M	98.31M	65.66M	21.72M	4.71M
Capital Lease Obligations	0	0	22.64M	19.55M	15.97M	11.83M	7.03M	1.49M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	5.41M	5.82M	9M	32.34M	6.38M	12.83M	5.01M	1.88M	0
Total Liabilities	112.22M	224.82M	217.44M	250.17M	229.03M	200.45M	177.09M	121.21M	85.96M
Total Debt	48.48M	151.89M	120.23M	120.95M	116.64M	114.28M	111.49M	74.08M	28.55M
Net Debt	-33.22M	43.49M	60.19M	35.66M	53.51M	38.08M	26.91M	4.86M	-1.09M
Debt / Equity	0.91x	4.43x	6.88x	-	-	5.29x	2.09x	0.80x	0.22x
Debt / EBITDA	-	-	-	-	9.26x	3.41x	2.52x	1.74x	0.59x
Net Debt / EBITDA	-	-	-	-	4.25x	1.13x	0.61x	0.11x	-0.02x
Interest Coverage	-404.49x	-9.33x	-4.03x	-3.26x	-1.25x	1.04x	2.70x	2.94x	6.40x
Total Equity	53.3M▲ 0%	34.31M▼ 35.6%	17.46M▼ 49.1%	-5.95M▼ 134.1%	-2.45M▲ 58.9%	21.61M▲ 983.4%	53.44M▲ 147.3%	92.13M▲ 72.4%	130.34M▲ 41.5%
Equity Growth %	-74.59%	-35.64%	-49.1%	-134.08%	58.9%	983.4%	147.33%	72.38%	41.48%
Book Value per Share	1.43	0.90	0.45	-0.15	-0.06	0.48	1.12	1.88	2.57
Total Shareholders' Equity	53.3M	34.31M	17.46M	-5.95M	-2.45M	21.61M	53.44M	92.13M	130.34M
Common Stock	4K	4K	4K	4K	4K	5K	5K	5K	5K
Retained Earnings	-1.09B	-1.2B	-1.28B	-1.34B	-1.37B	-1.37B	-1.35B	-1.31B	-1.28B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-449K	-12K	62K	0	-2K	0	-4K	6K	36K
Minority Interest	0	0	0	0	0	0	0	0	0

PBYI Cash Flow Statement

Puma Biotechnology, Inc. (PBYI) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-172.5M	-24.1M	22.38M	800K	20.65M	-15.83M	27.01M	38.92M	41.8M
Operating CF Margin %	-622.74%	-9.6%	8.22%	0.36%	8.16%	-6.94%	11.46%	16.89%	18.3%
Operating CF Growth %	-21.74%	86.03%	192.85%	-96.42%	2481.25%	-176.64%	270.65%	44.09%	7.41%
Net Income	-291.95M	-113.58M	-75.59M	-59.99M	-29.13M	2K	21.59M	30.28M	31.11M
Depreciation & Amortization	2.81M	7.38M	8.08M	10.03M	11.3M	9.84M	11.52M	11.52M	10.94M
Stock-Based Compensation	108.73M	86.94M	57.33M	36.58M	32.63M	11.83M	10.25M	8.24M	6.94M
Deferred Taxes	0	5K	0	0	0	0	0	-7.08M	3.25M
Other Non-Cash Items	-30K	289K	9.28M	1.03M	7.15M	7M	1.51M	-519K	-358K
Working Capital Changes	7.94M	-5.14M	23.28M	13.16M	-1.31M	-44.5M	-17.85M	-3.54M	-10.08M
Change in Receivables	-9.67M	-11.1M	-8.12M	2.35M	-5.98M	-7.82M	-8.37M	16.34M	-21.28M
Change in Inventory	-2.03M	-596K	-545K	-284K	-3.65M	2.58M	-2.55M	-1.64M	3.21M
Change in Payables	7.66M	-7.01M	-1.53M	-7.11M	-902K	-4.73M	449K	-1.38M	-453K
Cash from Investing	-15.4M	-57.6M	5.16M	23.3M	-10.88M	7.1M	-19.13M	-20.44M	-36.19M
Capital Expenditures	-50.43M	-609K	-306K	-20.05M	0	-7M	-140K	-56K	-71K
CapEx % of Revenue	182.06%	0.24%	0.11%	8.91%	-	3.07%	0.06%	0.02%	0.03%
Acquisitions	36K	193K	0	20M	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-15.01M	-170K	0	-20.1M	0	0	-12.5M	0	0
Cash from Financing	75.1M	108.4M	-67.07M	100K	-31.93M	12.22M	0	-33.85M	-45.2M
Debt Issued (Net)	50M	105M	-55M	0	-1.5M	0	0	-33.33M	-44.44M
Equity Issued (Net)	0	0	0	68K	0	12.5M	0	150K	130K
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0
Other Financing	25.11M	3.45M	-12.07M	32K	-30.43M	-277K	0	-666K	-888K
Net Change in Cash	-112.8M▲ 0%	26.72M▲ 123.7%	-39.53M▼ 247.9%	24.24M▲ 161.3%	-22.16M▼ 191.4%	3.5M▲ 115.8%	7.88M▲ 125.3%	-15.37M▼ 294.9%	-39.58M▼ 157.6%
Free Cash Flow	-222.93M▲ 0%	-24.71M▲ 88.9%	22.07M▲ 189.3%	-19.25M▼ 187.2%	20.65M▲ 207.3%	-22.83M▼ 210.5%	14.37M▲ 162.9%	38.86M▲ 170.5%	41.73M▲ 7.4%
FCF Margin %	-804.81%	-9.84%	8.11%	-8.55%	8.16%	-10.01%	6.1%	16.86%	18.27%
FCF Growth %	-49.63%	88.92%	189.32%	-187.2%	207.3%	-210.54%	162.95%	170.46%	7.38%
FCF per Share	-6.00	-0.65	0.57	-0.49	0.51	-0.51	0.30	0.79	0.82
FCF Conversion (FCF/Net Income)	0.59x	0.21x	-0.30x	-0.01x	-0.71x	-7913.50x	1.25x	1.29x	1.34x
Interest Paid	0	8.05M	11.74M	9.7M	10.34M	10.32M	11.63M	10.77M	0
Taxes Paid	0	17K	53K	207K	324K	384K	737K	1.22M	0

PBYI Key Ratios

Puma Biotechnology, Inc. (PBYI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-132.76%	-221.97%	-259.34%	-292.05%	-1042.3%	-	0.02%	57.54%	41.6%	27.97%
Return on Invested Capital (ROIC)	-218.71%	-1239.79%	-145.14%	-72.95%	-42.47%	2.4%	32.13%	34.96%	26.19%	24.73%
Gross Margin	-	79.78%	86.22%	86.48%	82.51%	74.84%	75.84%	73.4%	72.06%	74.53%
Net Margin	-	-1054.15%	-45.26%	-27.77%	-26.65%	-11.51%	0%	9.16%	13.14%	13.62%
Debt / Equity	-	0.91x	4.43x	6.88x	-	-	5.29x	2.09x	0.80x	0.22x
Interest Coverage	-288.72x	-404.49x	-9.33x	-4.03x	-3.26x	-1.25x	1.04x	2.70x	2.94x	6.40x
FCF Conversion	0.51x	0.59x	0.21x	-0.30x	-0.01x	-0.71x	-7913.50x	1.25x	1.29x	1.34x
Revenue Growth	-	-	806.14%	8.47%	-17.32%	12.46%	-9.92%	3.34%	-2.19%	-0.91%

PBYI SEC Filings & Documents

Puma Biotechnology, Inc. (PBYI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Feb 26, 2026·SEC

Material company update

Nov 6, 2025·SEC

Material company update

Aug 7, 2025·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

PBYI Frequently Asked Questions

Puma Biotechnology, Inc. (PBYI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Puma Biotechnology, Inc. (PBYI) reported $228.4M in revenue for fiscal year 2025.

Puma Biotechnology, Inc. (PBYI) saw revenue decline by 0.9% over the past year.

Yes, Puma Biotechnology, Inc. (PBYI) is profitable, generating $31.1M in net income for fiscal year 2025 (13.6% net margin).

Dividend & Returns

Puma Biotechnology, Inc. (PBYI) has a return on equity (ROE) of 28.0%. This is excellent, indicating efficient use of shareholder capital.

Puma Biotechnology, Inc. (PBYI) generated $41.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More PBYI

Puma Biotechnology, Inc. (PBYI) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Puma Biotechnology, Inc.(PBYI)Earnings, Financials & Key Ratios

PBYI Key Insights

✓Strengths

✗Weaknesses

PBYI Price & Volume

PBYI Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

PBYI Recent Earnings

PBYI Peer Comparison

Compare PBYI vs Peers

vs RCUS

vs AZN

Compare Top 5

PBYI Income Statement

PBYI Balance Sheet

PBYI Cash Flow Statement

PBYI Key Ratios

PBYI SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

PBYI Frequently Asked Questions

Explore More PBYI

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation